Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): Results of a phase 3, open-label, randomised trial

The Lancet Oncology

Volumn 16, Issue 13, 2015, Pages 1389-1398

  Grob, Jean Jacques ^a   Amonkar, Mayur M ^b   Karaszewska, Boguslawa ^c   Schachter, Jacob ^d   Dummer, Reinhard ^e   Mackiewicz, Andrzej ^f   Stroyakovskiy, Daniil ^g   Drucis, Kamil ^h   Grange, Florent ⁱ   Chiarion Sileni, Vanna ^j   Rutkowski, Piotr ^k   Lichinitser, Mikhail ^l   Levchenko, Evgeny ^m   Wolter, Pascal ⁿ   Hauschild, Axel ^o   Long, Georgina V ^p   Nathan, Paul ^q   Ribas, Antoni ^r   Flaherty, Keith ^s   Sun, Peng ^t   Legos, Jeffrey J ^b   McDowell, Diane Opatt ^b   Mookerjee, Bijoyesh ^b   Schadendorf, Dirk ^t   Robert, Caroline ^u   more..

^a AIX MARSEILLE UNIVERSITY   (France)

^b GLAXOSMITHKLINE   (United States)

^c Przychodnia Lekarska KOMED   (Poland)

^d SHEBA MEDICAL CENTER   (Israel)

^e UNIVERSITY OF ZURICH   (Switzerland)

^f POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^g Moscow City Oncology Hospital 62   (Russian Federation)

^h MEDICAL UNIVERSITY OF GDANSK   (Poland)

ⁱ REIMS UNIVERSITY HOSPITAL   (France)

^j VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^k INSTITUTE OF ONCOLOGY   (Poland)

^l N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

^m N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

ⁿ Katholieke Universiteit   (Belgium)

^o UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^p UNIVERSITY OF SYDNEY   (Australia)

^q MOUNT VERNON CANCER CENTRE   (United Kingdom)

^r UNIVERSITY OF CALIFORNIA   (United States)

^s MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^t UNIVERSITY HOSPITAL ESSEN   (Germany)

^u INSTITUT GUSTAVE ROUSSY   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; DABRAFENIB; TRAMETINIB; VALINE; VEMURAFENIB; ANTINEOPLASTIC AGENT; BRAF PROTEIN, HUMAN; IMIDAZOLE DERIVATIVE; INDOLE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; OXIME; PROTEIN KINASE INHIBITOR; PYRIDONE DERIVATIVE; PYRIMIDINONE DERIVATIVE; SULFONAMIDE; TUMOR MARKER;

ADULT; ARTICLE; BRAF GENE; CANCER CHEMOTHERAPY; CANCER GROWTH; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DYSPNEA; FATIGUE; FEMALE; FINANCIAL DEFICIT; FUNCTIONAL STATUS; GENE MUTATION; HEALTH STATUS; HUMAN; INSOMNIA; LOSS OF APPETITE; MAJOR CLINICAL STUDY; MALE; METASTATIC MELANOMA; MULTICENTER STUDY; NAUSEA AND VOMITING; OPEN STUDY; OVERALL SURVIVAL; PAIN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; GENETIC PREDISPOSITION; GENETICS; INTENTION TO TREAT ANALYSIS; MELANOMA; METABOLISM; MORTALITY; MUTATION; NUCLEOTIDE SEQUENCE; ORAL DRUG ADMINISTRATION; PATHOLOGY; PHENOTYPE; PROSPECTIVE STUDY; QUESTIONNAIRE; RISK FACTOR; SECONDARY; SKIN NEOPLASMS; TIME;

ADMINISTRATION, ORAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; DRUG ADMINISTRATION SCHEDULE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMIDAZOLES; INDOLES; INTENTION TO TREAT ANALYSIS; MAP KINASE KINASE KINASES; MELANOMA; MUTATION; OXIMES; PHENOTYPE; PROSPECTIVE STUDIES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; PYRIDONES; PYRIMIDINONES; QUALITY OF LIFE; RISK FACTORS; SKIN NEOPLASMS; SULFONAMIDES; SURVEYS AND QUESTIONNAIRES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84953924127     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)00087-X     Document Type: Article

References (26)

1. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954.
2. Jakob JA, Bassett RL, Ng CS, et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 2012, 118:4014-4023.
3. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011, 364:2507-2516.
4. Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012, 380:358-365.
5. Sondak VK, Flaherty LE Targeted therapies: improved outcomes for patients with metastatic melanoma. Nat Rev Clin Oncol 2011, 8:513-515.
6. Chapman PB, Hauschild A, Robert C, et al. Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAFV600E-mutated melanoma. Proc Am Soc Clin Oncol 2012, 30(suppl). abstr 8502.
7. Hauschild A, Grob JJ, Demidov LV, et al. An update on BREAK-3, a phase III, randomized trial: dabrafenib (DAB) versus dacarbazine (DTIC) in patients with BRAF V600E-positive mutation metastatic melanoma (MM). Proc Am Soc Clin Oncol 2013, 31. abstr 9013.
8. Long GV, Stroyakovskiy D, Gogas H, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med 2014, 371:1877-1888.
9. Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 2015, 372:30-39.
10. Larkin J, Ascierto PA, Dréno B, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 2014, 371:1867-1876.
11. Grob JJ, Amonkar MM, Martin-Algarra S, et al. Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine. Ann Oncol 2014, 25:1428-1436.
12. European organisation for research and treatment of cancer: EORTC quality of life questionnaire (EORTC QLQ-C30) (accessed Aug 20, 2015). http://groups.eortc.be/qol/eortc-qlq-c30.
13. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993, 85:365-376.
14. Kind P The EuroQoL instrument: an index of health-related quality of life. Quality of life and pharmacoeconomics in clinical trials 1996 1996, 191-201. Lippincott-Raven, Philadelphia. 2nd edn. B. Spilker (Ed.).
15. Rabin R, Charro F EQ-SD: a measure of health status from the EuroQol Group. Ann Med 2001, 33:337-343.
16. Cormier JN, Davidson L, Xing Y, Webster K, Cella D Measuring quality of life in patients with melanoma: development of the FACT-melanoma subscale. J Support Oncol 2005, 3:139-145.
17. Osoba D, Aaronson N, Zee B, Sprangers M, te Velde A Modification of the EORTC QLQ-C30 (version 2.0) based on content validity and reliability testing in large samples of patients with cancer. The Study Group on Quality of Life of the EORTC and the Symptom Control and Quality of Life Committees of the NCI of Canada Clinical Trials Group. Qual Life Res 1997, 6:103-108.
18. Osoba D, Zee B, Pater J, Warr D, Kaizer L, Latreille J Psychometric properties and responsiveness of the EORTC quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer. Qual Life Res 1994, 3:353-364.
19. Hjermstad MJ, Fossa SD, Bjordal K, Kaasa S Test/retest study of the European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire. J Clin Oncol 1995, 13:1249-1254.
20. Kaasa S, Bjordal K, Aaronson N, et al. The EORTC core quality of life questionnaire (QLQ-C30): validity and reliability when analysed with patients treated with palliative radiotherapy. Eur J Cancer 1995, 31A:2260-2263.
21. Osoba D, Rodrigues G, Myles J, Zee B, Pater J Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998, 16:139-144.
22. Pickard AS, Neary MP, Cella D Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes 2007, 5:70.
23. Cormier JN, Ross MI, Gershenwald JE, et al. Prospective assessment of the reliability, validity, and sensitivity to change of the functional assessment of cancer Therapy-Melanoma questionnaire. Cancer 2008, 112:2249-2257.
24. Askew RL, Xing Y, Palmer JL, Cella D, Moye LA, Cormier JN Evaluating minimal important differences for the FACT-Melanoma Quality of Life Questionnaire. Value Health 2009, 12:1144-1150.
25. Scott NW, Fayers PM, Aaronson NK, et al. EORTC QLQ-C30 Reference Values (accessed Aug 20, 2015). http://groups.eortc.be/qol/sites/default/files/img/newsletter/reference:values_manual2008.pdf.
26. Schadendorf D, Amonkar M, Stroyakovskiy D, et al. COMBI-d: Quality of life (QOL) impact of the combination of dabrafenib and trametinib (D+T) versus dabrafenib monotherapy (D) in patients with BRAF V600E/K unresectable or metastatic melanoma in a Phase III trial (1091). Ann Oncol 2014, 25(suppl 4):iv374-iv393.